Menu

Close

Sign InSign Out
ProductsOrderOrder
​​​​​​​
See all
Co-pay cards & patient savings offersMaterialsSamples*Hospital products*Vaccines, biologics & small-molecule medicines**​​​​​​​​​​​​​​​​​​​​​
Patient AssistancePatient Assistance

Find available assistance programsGo to Patient Assistance
Pfizer Oncology TogetherPfizer RxPathways
Explore contentExplore content

Explore more content
EventsVideosMaterials
ContactContact

See all Contact
Pfizer corporateAsk a question

Menu

Close

    AboutAbout

    Mechanism of ActionNCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)Identifying Patients With gBRCA Mutations
    Efficacy & SafetyEfficacy & SafetyStudy DesignEfficacySafety profileDosingDosing

    Dosing and Modifications
    Support & OrderSupport & Order

    EventsVideosMaterialsAccess & Patient Support

    Access and Patient Support

    Making your patients’ support needs a priority. Together.

    ** This is an optional area where footnotes can live.

    At Pfizer Oncology Together™, patient support is at the core of everything we do. We’ve gathered resources and developed tools to help patients and their loved ones throughout TALZENNA treatment. From helping to identify financial assistance options to connecting patients to resources for emotional support, your patients’ needs are our priority.

    Personalized Patient Support

    When your patients need support for their day-to-day challenges, we want to be a place they can turn to for help. At Pfizer Oncology Together, our Care Champions, who have social work experience, can connect patients prescribed TALZENNA to resources that may help with some of their daily needs.*

    Emotional support

    We can connect patients to diagnosis-specific support groups, an independent organization that offers short-term counseling, and a free app, developed by Pfizer Oncology, to help patients connect with loved ones and ask for the support they need

    Educational support

    To help support patients’ overall health and well-being, we’ve created resources about physical and mental health, as well as nutritional tips and healthy recipes developed in partnership with dietitians who specialize in oncology nutrition. We can also provide patients with information to help them understand their prescribed TALZENNA

    Practical support 

    If patients need assistance with transportation or lodging for treatment-related appointments, we’ll connect them to independent organizations that offer these services for free to qualifying patients

    And if your patients are leaving work for a period of time during treatment, or preparing to return to work, we can send them information to help make the transition easier​​​​​​​

      *Some services are provided through third-party organizations that operate independently and are not controlled by Pfizer. Availability of services and eligibility requirements are determined solely by these organizations.​​​​​​​

    Patient Financial Assistance 

    Pfizer Oncology Together can help patients understand their benefits and connect them with financial assistance resources, regardless of their insurance coverage.​​​​​​​

    Commercially insured

    ​​​Resources for eligible commercial, private, employer, and state health insurance marketplace patients:

    Co-pay card

    Co-pay assistance: Eligible, commercially insured patients may pay as little as $0 per month, regardless of income. There are no income requirements, forms, or faxing to enroll

    Get card now

        †Limits, terms, and conditions apply. Patients are not eligible to use this card if they are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veterans Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico. Patients may receive up to $25,000 per product in savings annually. The offer will be accepted only at participating pharmacies. This offer is not health insurance. No membership fees apply. Pfizer reserves the right to rescind, revoke, or amend this offer without notice. For any questions, please call 1-877-744-5675, visit PfizerOncologyTogether.com/terms or write: Pfizer Oncology Together Co-Pay Savings Program, 2250 Perimeter Park Drive, Suite 300, Morrisville, NC 27560.

    For more information, see your Pfizer Oncology representative, or visit www.PfizerOncologyTogether.com.

    Medicare/Government Insured

    Help identifying resources for eligible patients with Medicare/Medicare Part D, Medicaid, and other government insurance plans:

    • Assistance for patients with searching for financial support that may be available from independent charitable foundations. These foundations exist independently of Pfizer and have their own eligibility criteria and application processes. Availability of support from the foundations is determined solely by the foundations
    • Financial assistance through Extra Help, a Medicare Part D Low-Income Subsidy (LIS) program
    • Free medication§

     ‡”Covered” — TALZENNA is included on formulary/plan policies. Additional requirements may apply. Formulary data is current as of 11/2020.

      §If support from independent charitable foundations or Medicare Extra Help is not available, Pfizer Oncology Together will provide eligible patients with medication for free through the Pfizer Patient Assistance Program. The Pfizer Patient Assistance Program is a joint program of Pfizer Inc. and the Pfizer Patient Assistance Foundation™. The Pfizer Patient Assistance Foundation is a separate legal entity from Pfizer Inc. with distinct legal restrictions.

    Uninsured

    Help identifying resources for eligible patients without any form of healthcare coverage:

    • Help finding coverage
    • Free medication through the Pfizer Patient Assistance Program, or at a savings through the Pfizer Savings Program

       ‖The Pfizer Savings Program is not health insurance. For more information, call the toll-free number 1-877-744-5675. There are no membership fees to participate in this program. Estimated savings are 50% and depend on such factors as the particular drug purchased, amount purchased, and the pharmacy where purchased.

    Access & Reimbursement Support

    If patients prescribed TALZENNA need access or reimbursement support, Pfizer Oncology Together is here to help with:

    Benefits verification

    We can help determine a patient’s coverage and out-of-pocket costs

    Prior authorizations (PA)

    We can coordinate with a patient's insurer to determine the PA requirements. After your office submits a PA request, we'll follow up with the payer until a final outcome is determined.

    Appeals assistance

    We can help you and your office staff understand the payer requirements as you prepare an appeal submission. After your office submits an appeal, we’ll follow up with the payer to track its progress until a final outcome is determined.

    Speciality pharmacy coordination

    To help patients access the medication you’ve prescribed, we can identify specialty pharmacy options. If you prefer, you and your staff can also continue to work directly with specialty pharmacies.

    Dedicated local support

    Pfizer Oncology Account Specialists can provide detailed information on Pfizer Oncology medications and access resources. In addition, they can help you and your office staff contact a Pfizer Oncology Field Reimbursement Manager (FRM) in your area.
    ​​​​​​​
    FRMs are trained to help address specific access issues—in person or over the phone. They can help educate your staff on our access and reimbursement resources and help address challenging or urgent Pfizer Oncology patient cases you have sent to Pfizer Oncology Together.

    Pfizer Oncology together™ provides personalized support and financial assistance resources to help patients access their prescribed Pfizer Oncology medications.

    For Live, personalized support

    Call 1-877-774-5675 (Monday – Friday 8am – 8pm ET)

    Visit Pfizer Oncology Together

    GIVE YOUR PATIENTS A BIOMARKER-DRIVEN TREATMENT THAT'S ​​​​​​​JUST FOR THEM

    The card body Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam.

    Card CTA

    ** This is an optional area where footnotes can live.

    Identifying patients with gBRCA ​​​​​​​mutations

    Learn about the guidelines for gBRCA testing

    View testing guidelines

    ** This is an optional area where footnotes can live.

    Safety and tolerability profile

    The safety of TALZENNA was evaluated in an open-label, 2:1 randomised Phase 3 study1,3

    Review safety profile

    ** This is an optional area where footnotes can live.

    Convenient once-daily dosing​​​​​​​1

    The recommended starting dose of TALZENNA is 1 mg taken orally once daily1

    See dosing information

    ** This is an optional area where footnotes can live.


    References:
    1. TALZENNA [prescribing information]. New York, NY: Pfizer Inc.; 2020.
    2. Data on file. Pfizer Inc., New York, NY.
    3. Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379(8):753-763.

    Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML) have been reported in patients who received TALZENNA. Overall, MDS/AML has been reported in 2 out of 584 (0.3%) solid tumor patients treated with TALZENNA in clinical studies. The duration of TALZENNA treatment in these two patients prior to developing MDS/AML was 4 months and 24 months, respectively. Both patients had received previous chemotherapy with platinum agents and/or other DNA damaging agents including radiotherapy.

    Myelosuppression consisting of anemia, leukopenia/neutropenia, and/or thrombocytopenia have been reported in patients treated with TALZENNA. Grade ≥3 anemia, neutropenia, and thrombocytopenia were reported, respectively, in 39%, 21%, and 15% of patients receiving TALZENNA. Discontinuation due to anemia, neutropenia, and thrombocytopenia occurred, respectively, in 0.7%, 0.3%, and 0.3% of patients.

    Monitor complete blood counts for cytopenia at baseline and monthly thereafter. Do not start TALZENNA until patients have adequately recovered from hematological toxicity caused by previous therapy. If hematological toxicity occurs, dose modifications (dosing interruption with or without dose reduction) are recommended. With respect to MDS/AML, for prolonged hematological toxicities, interrupt TALZENNA and monitor blood counts weekly until recovery. If the levels have not recovered after 4 weeks, refer the patient to a hematologist for further investigations. If MDS/AML is confirmed, discontinue TALZENNA.

    TALZENNA can cause fetal harm when administered to pregnant women. Advise women of reproductive potential to use effective contraception during treatment and for at least 7 months following the last dose. A pregnancy test is recommended for females of reproductive potential prior to initiating TALZENNA treatment. Advise male patients with female partners of reproductive potential or who are pregnant to use effective contraception during treatment with TALZENNA and for at least 4 months after receiving the last dose. Based on animal studies, TALZENNA may impair fertility in males of reproductive potential. Advise women not to breastfeed while taking TALZENNA and for at least 1 month after receiving the last dose because of the potential for serious adverse reactions in nursing infants.

    The most common adverse reactions (≥20%) of any grade for TALZENNA vs chemotherapy were fatigue (62% vs 50%), anemia (53% vs 18%), nausea (49% vs 47%), neutropenia (35% vs 43%), headache (33% vs 22%), thrombocytopenia (27% vs 7%), vomiting (25% vs 23%), alopecia (25% vs 28%), diarrhea (22% vs 26%), and decreased appetite (21% vs 22%).

    The most frequently reported Grade ≥3 adverse reactions (≥10%) for TALZENNA vs chemotherapy were anemia (39% vs 5%), neutropenia (21% vs 35%), and thrombocytopenia (15% vs 2%).

    The most common lab abnormalities (≥25%) for TALZENNA vs chemotherapy were decreases in hemoglobin (90% vs 77%), leukocytes (84% vs 73%), lymphocytes (76% vs 53%), neutrophils (68% vs 70%), platelets (55% vs 29%), and calcium (28% vs 16%) and increases in glucose (54% vs 51%), aspartate aminotransferase (37% vs 48%), alkaline phosphatase (36% vs 34%), and alanine aminotransferase (33% vs 37%).

    Coadministration with P-gp inhibitors or BCRP inhibitors may increase TALZENNA exposure. If coadministering with the P-gp inhibitors amiodarone, carvedilol, clarithromycin, itraconazole, or verapamil is unavoidable, reduce the TALZENNA dose to 0.75 mg once daily. When the P-gp inhibitor is discontinued, increase the TALZENNA dose (after 3–5 half-lives of the P-gp inhibitor) to the dose used prior to the initiation of the P-gp inhibitor. When coadministering TALZENNA with other known P-gp inhibitors or BCRP inhibitors, monitor patients for potential increased adverse reactions.

    For patients with moderate renal impairment, the recommended dose of TALZENNA is 0.75 mg once daily. For patients with severe renal impairment, the recommended dose of TALZENNA is 0.5 mg once daily. No dose adjustment is required for patients with mild renal impairment. TALZENNA has not been studied in patients requiring hemodialysis.

    TALZENNA has not been studied in patients with moderate or severe hepatic impairment. No dose adjustment is required for patients with mild hepatic impairment.

    TALZENNA is indicated for the treatment of adult patients with deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA)-mutated (gBRCAm) human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Select patients for therapy based on an FDA-approved companion diagnostic for TALZENNA ​​​​​.

    Please see full Prescribing Information.

    Indication

    TALZENNA is indicated for the treatment of adult patients with deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA)-mutated (gBRCAm) human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Select patients for therapy based on an FDA-approved companion diagnostic for TALZENNA.